Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Annette Reichardt; Jörg T Hartmann; Daniel Pink; Giuliano Ramadori; Peter Hohenberger; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Bengt Nilsson; Harri Sihto; Petri Bono; Raija Kallio; Jouni Junnila; Thor Alvegård; Peter Reichardt

doi:10.1200/JCO.2015.62.9170

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Jörg T Hartmann, Daniel Pink, Giuliano Ramadori, Peter Hohenberger, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Bengt Nilsson, Harri Sihto, Petri Bono, Raija Kallio, Jouni Junnila, Thor Alvegård, Peter Reichardt

Research output: Contribution to journal › Article › peer-review

Abstract

Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial.

Original language	English
Pages (from-to)	244-250
Journal	Journal of Clinical Oncology
Volume	34
Issue number	3
Early online date	2015 Nov 2
DOIs	https://doi.org/10.1200/JCO.2015.62.9170
Publication status	Published - 2016

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2015.62.9170

http://www.ncbi.nlm.nih.gov/pubmed/26527782?dopt=Abstract

Cite this

Joensuu, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hartmann, J. T., Pink, D., Ramadori, G., Hohenberger, P., Al-Batran, S.-E., Schlemmer, M., Bauer, S., Wardelmann, E., Nilsson, B., Sihto, H., Bono, P., Kallio, R., Junnila, J., Alvegård, T., & Reichardt, P. (2016). Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of Clinical Oncology, 34(3), 244-250. https://doi.org/10.1200/JCO.2015.62.9170

@article{2997816b44eb4b719d3fa21e14b68365,

title = "Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.",

abstract = "Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial.",

author = "Heikki Joensuu and Mikael Eriksson and {Sundby Hall}, Kirsten and Annette Reichardt and Hartmann, {J{\"o}rg T} and Daniel Pink and Giuliano Ramadori and Peter Hohenberger and Salah-Eddin Al-Batran and Marcus Schlemmer and Sebastian Bauer and Eva Wardelmann and Bengt Nilsson and Harri Sihto and Petri Bono and Raija Kallio and Jouni Junnila and Thor Alveg{\aa}rd and Peter Reichardt",

year = "2016",

doi = "10.1200/JCO.2015.62.9170",

language = "English",

volume = "34",

pages = "244--250",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "3",

}

Joensuu, H, Eriksson, M, Sundby Hall, K, Reichardt, A, Hartmann, JT, Pink, D, Ramadori, G, Hohenberger, P, Al-Batran, S-E, Schlemmer, M, Bauer, S, Wardelmann, E, Nilsson, B, Sihto, H, Bono, P, Kallio, R, Junnila, J, Alvegård, T & Reichardt, P 2016, 'Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.', Journal of Clinical Oncology, vol. 34, no. 3, pp. 244-250. https://doi.org/10.1200/JCO.2015.62.9170

TY - JOUR

T1 - Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

AU - Joensuu, Heikki

AU - Eriksson, Mikael

AU - Sundby Hall, Kirsten

AU - Reichardt, Annette

AU - Hartmann, Jörg T

AU - Pink, Daniel

AU - Ramadori, Giuliano

AU - Hohenberger, Peter

AU - Al-Batran, Salah-Eddin

AU - Schlemmer, Marcus

AU - Bauer, Sebastian

AU - Wardelmann, Eva

AU - Nilsson, Bengt

AU - Sihto, Harri

AU - Bono, Petri

AU - Kallio, Raija

AU - Junnila, Jouni

AU - Alvegård, Thor

AU - Reichardt, Peter

PY - 2016

Y1 - 2016

N2 - Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial.

AB - Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial.

U2 - 10.1200/JCO.2015.62.9170

DO - 10.1200/JCO.2015.62.9170

M3 - Article

C2 - 26527782

SN - 1527-7755

VL - 34

SP - 244

EP - 250

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 3

ER -

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this